Added to YB: 2025-08-14
Pitch date: 2025-08-12
HROW [neutral]
Harrow, Inc.
+30.79%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
$1.6B
Pitch Price
$35.98
Price Target
N/A
Dividend
N/A
EV/EBITDA
38.20
P/E
-324.83
EV/Sales
7.29
Sector
Pharmaceuticals
Category
growth
HROW Second Quarter 2025 Earnings results
HROW (earnings update): Q2 revs +30% YOY to $63.7M, GAAP income $5M, Adj EBITDA $17M. VEVYE gaining 3% market share w/ 66% sequential Rx growth, expected to exceed $100M quarterly. Apollo Care alliance accelerating VAFA program. Samsung Bioepis ophthalmology biosimilar acquisition and BYQLOVI add growth. 2025 revenue >$280M with minimal costs.
Read full article (2 min)